A Three Gene Immunohistochemical Panel Serves for Patients with Head and Neck Cancer


Current management of head and neck squamous cell carcinoma (HNSCC) depends on tumor staging. Despite refinements in clinical staging algorithms, outcomes remain unchanged for the last two decades. In this study, we set out to identify a small, clinically applicable molecular panel to aid prognostication of patients with HNSCC. 

The objective of this study was to utilize publically-available expression and genomic data from The Cancer Genome Atlas (TCGA) to identify a suite of putative molecular prognostic markers, and validate these using IHC on tissue microarrays, in a completely different population cohort, in concert with a range of clinic-pathologic factors.



Read More ...

Changes in Uninvolved Immunoglobulins for Newly Diagnosed Multiple Myeloma


Multiple myeloma (MM) is a clonal plasma cell proliferative disorder that is predicted to account for >15% of all hematologic malignancies diagnosed in the United States this year. The majority of patients present with an elevated monoclonal protein, and a reduction in one or more uninvolved, polyclonal immunoglobulin (Ig) is seen in 490% of patients, especially in individuals with IgA myeloma.



Read More ...

Cancer Immunotherapy


The idea of exploiting the host’s immune system to treat cancer dates back decades and relies on the insight that the immune system can eliminate malignant cells during initial transformation in a process termed immune surveillance. Individual human tumors arise through a combination of genetic and epigenetic changes that facilitate immortality, but at the same time create foreign antigens, the so-called neo-antigens, which should render neoplastic cells detectable by the immune system and target them for destruction. 



Read More ...

Immunotherapy with Virus-Specific T Cells


Epstein-Barr virus (EBV) reactivation post allogeneic hematopoietic stem cell transplantation (HSCT) can lead to the outgrowth of EBV-infected B cells and the development of post-transplant lymphoproliferative disease (EBV-PTLD). In a series of Phase I and II clinical trials we have assessed the safety and clinical benefit associated with these transferred cells in allogeneic HSCT recipients. 



Read More ...

New Cancer Immunotherapy Agents in Development

In the wake of an unprecedented number of U.S. Food and Drug Administration (FDA) approvals for cancer immunotherapy agents, particularly immune checkpoint inhibitors, the field is poised for further advancement. An associated program of SITC’s 31st Annual Meeting in November 2016, the ‘New Cancer Immunotherapy Agents in Development’ session was organized through collaboration between the SITC Annual Program Committee and the SITC Industry Committee. 



Read More ...
RSS




123